Compare Harley-Davidson Inc (HOG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs TransMedics Group Inc — how do they compare? Harley-Davidson Inc trades at $25.96 (market cap $2.78B), while TransMedics Group Inc trades at $87.51 (market cap $3.10B). The key difference: Harley-Davidson Inc and TransMedics Group Inc are close in size by market cap, and Harley-Davidson Inc pays a 2.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| HOG | TMDX | |
|---|---|---|
Market Cap | $2.78B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $31.03 | $150.42 |
52-Week Low | $17.19 | $61.99 |
Enterprise Value | $3.19B | $3.49B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.10, up 0.35% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with an EPS beat ($0.75 vs. $0.645 expected) but revenue challenges, while raising full-year guidance. Valuation appears reasonable with P/E of 14.84 and P/S of 0.72, though profitability metrics show pressure with net margin at 4.78%.
The outlook remains cautiously optimistic with analyst consensus at $26.00 target. Key opportunities include North American sales strength and cost-cutting initiatives, while risks involve raw material costs and competitive pressures. Institutional activity shows mixed signals with recent large purchases and sales.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
